v3.26.1
Condensed Consolidated Statements of Equity (Deficit) - USD ($)
$ in Thousands
Total
Total Stockholders' Equity
Common Stock
Treasury Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Noncontrolling Interest
Mezzanine Equity at beginning of period (in shares) at Dec. 31, 2024 28,000.00001              
Mezzanine Equity at beginning of period at Dec. 31, 2024 $ 23,861              
Mezzanine Equity                
Conversion of convertible preferred stock (in shares) (7,000)              
Conversion of convertible preferred stock $ (7,000)              
Preferred stock accretion $ 1,513              
Mezzanine Equity at end of period (in shares) at Mar. 31, 2025 21,000.00001              
Mezzanine Equity at end of period at Mar. 31, 2025 $ 18,374              
Common stock, shares outstanding at beginning of period (in shares) at Dec. 31, 2024     89,861,035          
Stockholders' equity at beginning of period at Dec. 31, 2024   $ (7,731) $ 9 $ (5,445) $ 718,797 $ (27,455) $ (693,637)  
Stockholders’ Deficit                
Shares issued in connection with equity incentive plans (in shares)     288,846          
Stock-based compensation expense and vesting of restricted stock units   687     687      
Conversion of convertible preferred stock (in shares)     3,784,688          
Conversion of convertible preferred stock   7,000     7,000      
Preferred stock accretion (1,513) (1,513)     (1,513)      
Other   (40)         (40)  
Other comprehensive income (loss)   (741)       (741)    
Net loss $ (9,041) (9,041)         (9,041)  
Common stock, shares outstanding at end of period (in shares) at Mar. 31, 2025     93,934,569          
Stockholders' equity at end of period at Mar. 31, 2025   (11,379) $ 9 (5,445) 724,971 (28,196) (702,718)  
Common stock, shares outstanding at beginning of period (in shares) at Dec. 31, 2025 112,819,881   112,819,881          
Stockholders' equity at beginning of period at Dec. 31, 2025 $ 18,375 18,375 $ 11 (5,445) 757,441 (26,716) (706,916) $ 0
Stockholders’ Deficit                
Shares issued in connection with equity incentive plans (in shares)     2,141,091          
Stock-based compensation expense and vesting of restricted stock units 1,169 1,169     1,169      
Shares withheld for taxes in connection with vested restricted stock units (in shares)     (952,133)          
Shares withheld for taxes in connection with vested restricted stock units (1,828) (1,828)   (1,828)        
Preferred stock accretion 0              
Sale of common stock (in shares)     1,389,751          
Sale of common stock 2,538 2,538 $ 1   2,537      
Initial contribution 15,003 14,202     14,202     801
Noncontrolling interest capital contribution 2,402 2,402     2,402      
Other comprehensive income (loss) 592 592       592    
Net loss $ (3,963) (3,963)         (3,963)  
Common stock, shares outstanding at end of period (in shares) at Mar. 31, 2026 115,398,590   115,398,590          
Stockholders' equity at end of period at Mar. 31, 2026 $ 34,288 $ 33,487 $ 12 $ (7,273) $ 777,751 $ (26,124) $ (710,879) $ 801